China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026)
China Pharma Holdings (CPHI) posted Cash from Financing Activities of -$79325.0 for Q1 2026, down 9.28% on a QoQ basis from -$72592.0 in Q4 2025, and down 3.26% year-over-year from -$81998.9 in Q1 2025.
China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026) Analysis & Trends
China Pharma Holdings' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$79325.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 3.26% year-over-year to -$79325.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$296532.0 (down 152.46% YoY) and the FY2025 annual result came in at -$294027.0, down 770.37% from the prior year.
- Cash from Financing Activities was -$79325.0 for Q1 2026 at China Pharma Holdings, down from -$72592.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $518237.0 in Q1 2023 and bottomed at -$850555.0 in Q2 2022.
- A 5-year average of -$123764.5 and a median of -$54333.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 633.62% — and 2025, when it slumped 1885.97%.
- China Pharma Holdings' Cash from Financing Activities stood at -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then tumbled by 278.86% to -$54333.0 in 2024, then plunged by 33.61% to -$72592.0 in 2025, then fell by 9.28% to -$79325.0 in 2026.
- Business Quant data shows CPHI's Cash from Financing Activities at -$79325.0 in Q1 2026, -$72592.0 in Q4 2025, and -$122214.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -79,325.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,325.00 |
| Mar 31, 2026 | -79,325.00 |
| Dec 31, 2025 | -72,592.00 |
| Dec 31, 2025 | -72,592.00 |
| Sep 30, 2025 | -122,214.00 |
| Sep 30, 2025 | -122,214.00 |
| Jun 30, 2025 | -22,401.00 |
| Jun 30, 2025 | -22,401.00 |
| Mar 31, 2025 | -76,820.00 |
| Mar 31, 2025 | -76,820.00 |
| Dec 31, 2024 | -54,333.00 |
| Dec 31, 2024 | -54,333.00 |
| Sep 30, 2024 | 6,843.00 |
| Sep 30, 2024 | 6,843.00 |
| Jun 30, 2024 | 6,852.00 |
| Jun 30, 2024 | 6,852.00 |
| Mar 31, 2024 | 6,856.00 |
| Mar 31, 2024 | 6,856.00 |
| Dec 31, 2023 | 30,378.00 |
| Dec 31, 2023 | 30,378.00 |